I

Innate Pharma SA
D

IPHA

1.49000
USD
-0.01
(-0.67%)
مغلق
حجم التداول
33
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
120,616,665
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARCT
    -2.310
    (-12.60%)
    16.020 USD
    B
    BNTX
    -3.740
    (-3.61%)
    99.740 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    JNJ
    JNJ
    2.140
    (1.41%)
    155.390 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    103.080 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    N
    NVAX
    0.12000
    (1.67%)
    7.32500 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.830 USD
    المزيد
الأخبار

العنوان: Innate Pharma SA

القطاع: Healthcare
الصناعة: Biotechnology
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.